• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腱生蛋白-C:癌症治疗中的利用与附带损害

Tenascin-C: Exploitation and collateral damage in cancer management.

作者信息

Spenlé Caroline, Saupe Falk, Midwood Kim, Burckel Hélène, Noel Georges, Orend Gertraud

机构信息

a Inserm U1109, MN3T; Université de Strasbourg; Strasbourg, France; LabEx Medalis; Université de Strasbourg; Strasbourg, France. Fédération de Médecine Translationnelle de Strasbourg (FMTS) ; Strasbourg , France.

出版信息

Cell Adh Migr. 2015;9(1-2):141-53. doi: 10.1080/19336918.2014.1000074.

DOI:10.1080/19336918.2014.1000074
PMID:25569113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4422814/
Abstract

Despite an increasing knowledge about the causes of cancer, this disease is difficult to cure and still causes far too high a death rate. Based on advances in our understanding of disease pathogenesis, novel treatment concepts, including targeting the tumor microenvironment, have been developed and are being combined with established treatment regimens such as surgical removal and radiotherapy. Yet it is obvious that we need additional strategies to prevent tumor relapse and metastasis. Given its exceptional high expression in most cancers with low abundance in normal tissues, tenascin-C appears an ideal candidate for tumor treatment. Here, we will summarize the current applications of targeting tenascin-C as a treatment for different tumors, and highlight the potential of this therapeutic approach.

摘要

尽管人们对癌症病因的认识不断增加,但这种疾病难以治愈,死亡率仍然过高。基于我们对疾病发病机制的理解取得的进展,已经开发出了包括靶向肿瘤微环境在内的新治疗理念,并正在与手术切除和放疗等既定治疗方案相结合。然而,显然我们需要额外的策略来预防肿瘤复发和转移。鉴于腱生蛋白-C在大多数癌症中异常高表达,而在正常组织中含量较低,它似乎是肿瘤治疗的理想候选者。在这里,我们将总结靶向腱生蛋白-C作为不同肿瘤治疗方法的当前应用,并强调这种治疗方法的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea49/4422814/f92ddb35f992/kcam-09-141-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea49/4422814/f92ddb35f992/kcam-09-141-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea49/4422814/f92ddb35f992/kcam-09-141-g001.jpg

相似文献

1
Tenascin-C: Exploitation and collateral damage in cancer management.腱生蛋白-C:癌症治疗中的利用与附带损害
Cell Adh Migr. 2015;9(1-2):141-53. doi: 10.1080/19336918.2014.1000074.
2
Targeting the MAtrix REgulating MOtif abolishes several hallmarks of cancer, triggering antitumor immunity.靶向基质调节基序可消除癌症的多个特征,触发抗肿瘤免疫。
Proc Natl Acad Sci U S A. 2024 Oct 15;121(42):e2404485121. doi: 10.1073/pnas.2404485121. Epub 2024 Oct 9.
3
Advances on the roles of tenascin-C in cancer.层粘连蛋白 C 在癌症中的作用研究进展。
J Cell Sci. 2022 Sep 15;135(18). doi: 10.1242/jcs.260244. Epub 2022 Sep 14.
4
Matrix-Targeting Immunotherapy Controls Tumor Growth and Spread by Switching Macrophage Phenotype.基质靶向免疫疗法通过改变巨噬细胞表型控制肿瘤生长和扩散。
Cancer Immunol Res. 2020 Mar;8(3):368-382. doi: 10.1158/2326-6066.CIR-19-0276. Epub 2020 Jan 15.
5
Tenascin C in metastasis: A view from the invasive front.转移中的腱生蛋白C:来自侵袭前沿的视角
Cell Adh Migr. 2015;9(1-2):112-24. doi: 10.1080/19336918.2015.1008331.
6
Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival.定量蛋白质组学鉴定 Tenascin-C 是促进肺癌进展的促进因子,并有助于预测患者生存的特征。
Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):E5625-E5634. doi: 10.1073/pnas.1707054114. Epub 2017 Jun 26.
7
Impact of Tenascin-C on Radiotherapy in a Novel Syngeneic Oral Squamous Cell Carcinoma Model With Spontaneous Dissemination to the Lymph Nodes.层粘连蛋白 C 对新型同源性口腔鳞状细胞癌模型伴淋巴结自发转移放射治疗的影响。
Front Immunol. 2021 Jul 5;12:636108. doi: 10.3389/fimmu.2021.636108. eCollection 2021.
8
Spatial organization of the tenascin-C microenvironment in experimental and human cancer.实验性和人类癌症中肌腱蛋白-C微环境的空间组织
Cell Adh Migr. 2015;9(1-2):4-13. doi: 10.1080/19336918.2015.1005452.
9
Selection and characterization of tenascin C targeting peptide.靶向 tenascin C 的十肽的选择和鉴定。
Mol Cells. 2012 Jan;33(1):71-7. doi: 10.1007/s10059-012-2214-4. Epub 2011 Dec 1.
10
Tenascin-C induced signaling in cancer.肌腱蛋白-C在癌症中的诱导信号传导。
Cancer Lett. 2006 Dec 8;244(2):143-63. doi: 10.1016/j.canlet.2006.02.017. Epub 2006 Apr 24.

引用本文的文献

1
Revealing the structural microenvironment of high metastatic risk uveal melanomas following decellularisation.揭示去细胞化后高转移风险葡萄膜黑色素瘤的结构微环境。
Sci Rep. 2024 Nov 5;14(1):26811. doi: 10.1038/s41598-024-78171-2.
2
The axis of tumor-associated macrophages, extracellular matrix proteins, and cancer-associated fibroblasts in oncogenesis.肿瘤相关巨噬细胞、细胞外基质蛋白和癌症相关成纤维细胞在肿瘤发生中的作用轴。
Cancer Cell Int. 2024 Oct 7;24(1):335. doi: 10.1186/s12935-024-03518-8.
3
The Role of Tenascin-C in Hypertrophic Scar Formation: Insights from Cell and Animal Experiments.

本文引用的文献

1
Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer.针对纤连蛋白ED-A的治疗性疫苗接种可减缓转移性乳腺癌的进展。
Oncotarget. 2014 Dec 15;5(23):12418-27. doi: 10.18632/oncotarget.2628.
2
Phosphonated chelates for nuclear imaging.用于核医学成像的膦酸螯合物。
Org Biomol Chem. 2014 Dec 21;12(47):9601-20. doi: 10.1039/c4ob01514b. Epub 2014 Oct 23.
3
AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients.
肌腱蛋白-C在肥厚性瘢痕形成中的作用:来自细胞和动物实验的见解
Clin Cosmet Investig Dermatol. 2024 Jul 12;17:1637-1648. doi: 10.2147/CCID.S461760. eCollection 2024.
4
Extracellular matrix complexity in biomarker studies: a novel assay detecting total serum tenascin-C reveals different distribution to isoform-specific assays.生物标志物研究中的细胞外基质复杂性:一种新型检测总血清腱糖蛋白 C 的检测方法显示与同工型特异性检测方法不同的分布。
Front Immunol. 2023 Nov 22;14:1275361. doi: 10.3389/fimmu.2023.1275361. eCollection 2023.
5
Fibroblast diversity and plasticity in the tumor microenvironment: roles in immunity and relevant therapies.肿瘤微环境中成纤维细胞的多样性和可塑性:在免疫中的作用及相关治疗。
Cell Commun Signal. 2023 Sep 18;21(1):234. doi: 10.1186/s12964-023-01204-2.
6
Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases.从患者转移灶的细胞外基质成分中进行蛋白质组学分析,鉴定出一致升高的蛋白质,用于开发针对原发肿瘤和转移灶的纳米抗体。
Cancer Res. 2023 Jun 15;83(12):2052-2065. doi: 10.1158/0008-5472.CAN-22-1532.
7
Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions.癌症相关成纤维细胞对抗肿瘤免疫反应的调节:阻碍其免疫抑制功能的机制及靶向策略
Explor Target Antitumor Ther. 2022;3(5):598-629. doi: 10.37349/etat.2022.00103. Epub 2022 Oct 27.
8
Advances on the roles of tenascin-C in cancer.层粘连蛋白 C 在癌症中的作用研究进展。
J Cell Sci. 2022 Sep 15;135(18). doi: 10.1242/jcs.260244. Epub 2022 Sep 14.
9
Matricellular protein tenascin C: Implications in glioma progression, gliomagenesis, and treatment.基质细胞蛋白腱生蛋白C:在胶质瘤进展、胶质瘤发生及治疗中的意义
Front Oncol. 2022 Aug 12;12:971462. doi: 10.3389/fonc.2022.971462. eCollection 2022.
10
Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers.组织蛋白酶 K:一种用于多种癌症的多功能潜在生物标志物和治疗靶点。
Curr Oncol. 2022 Aug 22;29(8):5963-5987. doi: 10.3390/curroncol29080471.
血管基质(AngioMatrix)是肿瘤血管生成开关特异性基质组的一种特征,与胶质瘤和结直肠癌患者的不良预后相关。
Oncotarget. 2014 Nov 15;5(21):10529-45. doi: 10.18632/oncotarget.2470.
4
Recent advances in radiation oncology.放射肿瘤学的最新进展。
Int J Clin Oncol. 2014 Aug;19(4):563. doi: 10.1007/s10147-014-0720-4. Epub 2014 Jun 26.
5
Clinical significance of serum tenascin-c levels in epithelial ovarian cancer.血清腱生蛋白-C水平在上皮性卵巢癌中的临床意义
Tumour Biol. 2014 Jul;35(7):6777-82. doi: 10.1007/s13277-014-1923-z. Epub 2014 Apr 11.
6
Clinical significance of serum tenascin-C levels in breast cancer.血清腱生蛋白-C水平在乳腺癌中的临床意义
Tumour Biol. 2014 Jul;35(7):6619-25. doi: 10.1007/s13277-014-1875-3. Epub 2014 Apr 3.
7
Radiotherapy for renal-cell carcinoma.肾细胞癌的放射治疗。
Lancet Oncol. 2014 Apr;15(4):e170-7. doi: 10.1016/S1470-2045(13)70569-2.
8
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.用Tenarad进行放射免疫治疗,Tenarad是一种靶向腱生蛋白-C胞外结构域A1的131I标记抗体片段,用于难治性霍奇金淋巴瘤患者。
Eur J Nucl Med Mol Imaging. 2014 May;41(5):867-77. doi: 10.1007/s00259-013-2658-6. Epub 2014 Jan 17.
9
Comparative effectiveness research in practice and policy for radiation oncology.在放射肿瘤学实践和政策中的比较效果研究。
Semin Radiat Oncol. 2014 Jan;24(1):54-60. doi: 10.1016/j.semradonc.2013.09.001.
10
Comparative effectiveness research in radiation oncology: stereotactic radiosurgery, hypofractionation, and brachytherapy.放射肿瘤学中的比较疗效研究:立体定向放射外科、低分割和近距离放射治疗。
Semin Radiat Oncol. 2014 Jan;24(1):35-42. doi: 10.1016/j.semradonc.2013.08.004.